Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
Open Access
- 27 October 2008
- journal article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 8 (1), 14
- https://doi.org/10.1186/1472-6823-8-14
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responsesBMC Immunology, 2009
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesCurrent Medical Research and Opinion, 2008
- Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated AngioedemaHypertension, 2008
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007
- Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edemaJournal of Allergy and Clinical Immunology, 2007
- Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurrent Medical Research and Opinion, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trialDiabetes, Obesity and Metabolism, 2007
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- Triple therapy with glimepiride in patients with type 2diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group studyClinical Therapeutics, 2005